HER2-targeted antibody drug conjugate shows encouraging responses, long-lasting clini
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types.